The Influence of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Patients Undergoing Non-emergent Coronary Angiography

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-03-31

Study Completion Date

2010-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the current study is to evaluate prospectively whether concomitant administration of RAAS blockers (namely ACE-I and ARBs') influence the change in estimated GFR (eGFR) after administration of contrast media in patients undergoing non-emergent coronary angiography.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Renin-angiotensin-aldosterone System (RAAS) Blockade and Contrast Induced Nephropathy

NCT01525888

Radiographic Contrast Agent Nephropathy

COMPLETED NA

ACEIs and ARBs Treatment in Diabetic Patients -Drug Interactions and Adverse Drug Effects

NCT00437775

Diabetes Mellitus Type 2

UNKNOWN

Anti-Proteinuric Response to ACEI, ARB and Diuretics Combination.

NCT00200694

Heavy Proteinuria

TERMINATED PHASE4

Anti-Hypertensive Agent (ACEi) and Heart Function Improvement in Association With Rho Kinase Activity Changes in Human

NCT01069042

Heart Failure

UNKNOWN PHASE4

High Dose Ace Inhibitor Therapy Versus Combination of ACE and ARB Therapy

NCT00212901

Diabetic Kidney Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Blood Pressure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

continue ace-i and arb's versus dicontinue

Group Type NO_INTERVENTION

No interventions assigned to this group

group b

Group Type ACTIVE_COMPARATOR

stop ace-i/arb 24 h before procedure and restarted 24 hours after the procedure

Intervention Type DRUG

ACE/ARB stopped 24 hours prior to the procedure and restarted 24 hours after the procedure

group c

Group Type ACTIVE_COMPARATOR

ACE/ARB stopped 24 hours before procedure and start immediately after

Intervention Type DRUG

ACE/ARB stopped 24 hours prior to the procedure and restarted immediately after the procedure

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

stop ace-i/arb 24 h before procedure and restarted 24 hours after the procedure

ACE/ARB stopped 24 hours prior to the procedure and restarted 24 hours after the procedure

Intervention Type DRUG

ACE/ARB stopped 24 hours before procedure and start immediately after

ACE/ARB stopped 24 hours prior to the procedure and restarted immediately after the procedure

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Age\>18 years
* 2\. Subjects on chronic therapy with ACE-I and/or ARBs' (confirmed by electronic records in their medical file)
* 3\. Subjects planned to undergo non-emergent coronary angiography.
* 4\. Signed informed consent

Exclusion Criteria

* 1\. eGFR\<30 ml/min at baseline
* 2\. Chronic utilization of NSAIDS and Cox-2 selective inhibitors
* 3\. Chronic treatment with mineralocorticosteroid receptor blocker
* 4\. Systolic blood pressure\<90 mmHg
* 5\. Planned staged (repeated) procedure within 48 hours
* 6\. Administration of contrast within 14 days prior to the enrollment
* 7\. contraindication to stop ACE-I or ARB'S

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No